In-Line Assets
Maximize the Value of Your In-Line Assets—While Investing in What’s Next
Pharma is facing a growing gap between revenue at risk and new revenue generation:
- Loss of exclusivity is accelerating decline in established brands
- Pipeline and launches are not replacing lost revenue fast enough
- Commercial teams must deliver results with fewer resources
Result: Most pharma companies will lose more revenue from in-line assets than they gain from new launches—making lifecycle optimization a business imperative.
EVERSANA REIGNITE™
is an AI-enabled commercialization model designed to help pharmaceutical companies reduce cost, sustain revenue, and unlock value across the brand lifecycle.
Unlocking Value Through Quantified Lifecyle Optimization
-
>30%COST SAVINGS Achieved through advanced analytics, digital and AI capabilities
-
>10%ADDITIONAL REVENUE Delivered through target, channel and portfolio optimization
-
>10%RETAINED HCPS & PATIENTS Delivered through improved adherence and engaged HCPs
How We Deliver Value
Efficiency at Scale
Operate brands more efficiently—without sacrificing performance
- Reduce cost-to-serve through AI-enabled execution
- Optimize resource allocation across portfolios
- Enable scalable, centralized delivery models
Revenue Optimization & Growth
Sustain and grow revenue from existing assets
- Improve adherence and patient persistence
- Increase HCP engagement through targeted interventions
- Continuously test, learn, and optimize performance
AI-Enabled Commercial Model
A fundamentally new way to deliver commercialization at scale
- AI agency accelerates content creation and execution
- AI/virtual field extends reach beyond traditional models
- Shared execution reduces cost and increases speed to value
Explore these comprehensive services to support your mature brand strategy, including:
Reignite the Value of Your Portfolio
Whether your brand needs to recover, sustain, or maximize value, EVERSANA REIGNITE helps you do more with what you already have.
Let’s connect to explore how REIGNITE can transform your in-line portfolio.
Related Articles
Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products
The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product launches, mature brands are essentially starved of any resources to keep them healthy and vital, even if they are […]